Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Neoplasm Metastasis 6Metastatic Hormone-sensitive Prostate Cancer 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Stage I Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Recurrence 1Non-metastatic, Hormone naïve Prostate Cancer 1Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Lymphatic Metastasis 1Insulin Resistance 1Adenocarcinoma of the Prostate 1

Interventions

enzalutamide 9Abiraterone Acetate 5rucaparib 2Prednisone 2Docetaxel 2pembrolizumab 1fluzoparib 1apatinib 1abiraterone 1Blood Specimen Collection 1Biopsy 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration Resistant Prostate Cancer × Androgen Antagonists × Clear all
NCT03641560 2025-04-08

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Astellas Pharma Inc

Phase 4 Completed
52 enrolled 10 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡